Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Peregrine stops phase III bavituximab study in NSCLC following interim analysis

Feb. 26, 2016

Seattle Genetics initiates phase I trial of SGN-CD19B

Feb. 26, 2016

EMA approves development strategy for Mologen's lefitolimod

Feb. 25, 2016

Forty Seven reports on Series A financing to fund development of CD47 modulators

Feb. 25, 2016

OncBioMune reports phase I results for prostate cancer vaccine ProscaVax

Feb. 24, 2016

Promising phase II results for AdV-tk plus valacyclovir adjuvant to SOC in malignant glioma

Feb. 24, 2016

Seattle Genetics starts phase I/II trial of vadastuximab talirine in MDS

Feb. 23, 2016

OBI Pharma reports topline results for OBI-822/821 in patients with metastatic breast cancer

Feb. 23, 2016

Phase II trial explores use of glembatumumab vedotin in recurrent or refractory osteosarcoma

Feb. 23, 2016

Apogenix receives grant for immuno-oncology candidate and companion diagnostic

Feb. 17, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 15, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...